Sharline C. Email & Phone Number

- Played a pivotal role as part of the company's founding team, swiftly establishing functional labs within one month of joining.- Orchestrated coordination between the internal in vivo team and CRO to execute high-impact proof of concept and efficacy studies.- Collaborated effectively with CRO (Contract Research Organization) and consultants to establish robust PK (Pharmacokinetic) and PD (Pharmacodynamic) relationships.- Collaborated closely with study directors and toxicologists to determine the Maximum Tolerated Dose (MTD) in non-human primate studies, ensuring safe and effective dose levels for preclinical evaluations.

- Led the design and implementation of bispecific T cell engagers and immune-modulators for therapeutic candidates targeting inflammatory diseases.- Leveraged the inherent properties of IgM antibodies to explore proof of concept, mechanisms of action, and feasibility through in vitro and in vivo models.

- Successfully established functional T cell assays, contributing to the enhancement of the company's portfolio.- Co-led a project focused on meticulously examining and reproducing clinical findings through proficient in vitro and in vivo experiments.- Proactively identified potential targets and companies for external collaboration, fostering valuable partnerships.- Acted as a mentor to team members, providing guidance in multi-color flow and supporting their assay development efforts.

Associate Scientist, Cell Biology and Physiology, 2014 – 2018 - Spearheaded the identification of novel myeloid targets and successfully unraveled the functional mechanism for one of the preclinical targets. - Conducted extensive data mining and research on new targets, significantly enriching the company's portfolio.Research Associate III/IV, Cell Biology and Pharmacology, 2004 – 2014 - Successfully invented and patented a B-cell depletion assay using normal human and cynomolgus whole blood, as well as chronic patient samples. - Played a key role in characterizing CD30 and CD19 antibodies, both of which advanced to Phase I clinical trials. - Developed robust assay protocols for clinical trial monitoring of CXCL10, CXCR4, and Mesothelin-ADC antibodies. - Collaborated effectively with management and non-management personnel from diverse departments to contribute to pre-clinical study reports and early candidate nomination. - Authored and audited technical study reports, Investigator Brochures, and IND summaries, providing vital support for regulatory submissions. - Conducted pivotal experiments to validate in-license antibody technology opportunities.Research Associate II, Hybridoma, 2002 – 2004 - Successfully generated type I interferon alpha antibodies, which were licensed to MedImmune/AstraZeneca, and are now available in the market as anifrolumab. - Played a crucial role in identifying and resolving company-wide mycoplasma contamination issues, leading to the establishment of the QA/QC department. - Acted as a key contributor in initiating and implementing automated laboratory processes, which ultimately resulted in the formation of the hybridoma automation department.

Developed and established a cutting-edge chemotaxis assay utilizing the company's proprietary CytoChip and Autosampler, leading to successful VC funding.

Led the development, optimization, and validation of system parameters for therapeutic drugs and drugs of abuse assays on immunoassay analyzers, resulting in FDA approval.